Treatment-free remission (TFR) is feasible after 2 or more years of frontline nilotinib treatment in patients with chronic myeloid leukemia in chronic phase (CML-CP), reported researchers in a study published in Leukemia. Advances in the treatment of CML have improved outcomes for those with the disease; however, long-term treatment with tyrosine...
treatment News
A Kidney Disease: Improving Global Outcomes (KDIGO) committee has released a new 2021 clinical practice guideline that updates their 2012 recommendations for the management of lupus nephritis (LN) and other glomerular diseases. The new guideline presents recommendations and practice points on various glomerular diseases, including LN, IgA nephropathy and IgA...
DUBLIN – Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its strategic partner Mitsubishi Tanabe Pharma Corporation (MTPC) has received manufacturing and marketing approval of UPLIZNA for the prevention of relapses of neuromyelitis optica spectrum disorder (including neuromyelitis optica) from the Japanese Ministry of Health, Labour and Welfare. MTPC has rights to the development...
According to a report published in Blood, addition of the novel E-selectin inhibitor uproleselan to both an intensive chemotherapy-based salvage regimen and a standard intensive frontline regimen was safe, well tolerated, and active in patients with acute myeloid leukemia (AML). Expression of E-selectin in the bone marrow microenvironment contributes to drug...
PRINCETON, N.J. — UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced a licensing agreement with MEDAC GmbH to develop a next-generation novel mitomycin-based formulation for urothelial cancers. UGN-103, UroGen’s RTGel® technology combined with medac’s licensed mitomycin, is a...
Orphan Therapeutics, LLC and Ikaria Holdings, Inc announced that the US Food and Drug Administration (FDA) has accepted the final section of the New Drug Application (NDA) filing seeking marketing approval for Lucassin (terlipressin for injection) for the treatment of hepatorenal syndrome (HRS) Type-1. The filing was completed on May...
Basel, Switzerland – Sandoz, a global leader in biosimilar and generic medicines, today announced that the US Supreme Court has denied its petition to review the Federal Circuit’s July 2020 decision concerning the Sandoz biosimilar Erelzi® (etanercept-szzs) for reference medicine Enbrel®* (etanercept). The Federal Circuit previously ruled against Sandoz in...
Philadelphia, Pennsylvania – In the retinas of human eyes, the cones are photoreceptor cells responsible for color vision, daylight vision, and the perception of small details. As vision scientists from the Division of Experimental Retinal Therapies at the University of Pennsylvania School of Veterinary Medicine, Gustavo D. Aguirre and William A. Beltran have been working for...
Hong Kong – A crucial player in genomic integrity maintenance, DNA Polymerase Theta (Polθ) provides a potential synthetic lethal relationship in BRCA-deficient tumors, which are particularly prevalent in certain tumor types including triple-negative breast cancers (TNBC) and ovarian cancers. In fact, BRCA-deficient tumors account for 11-16% of TNBC cases, and...
SALT LAKE CITY, Utah — While many babies are born without issues on a daily basis, there are quite a few who are born early and with some complications. Those babies end up in the Neonatal Intensive Care Unit (NICU), which is where Dr. Sabrina Malone Jenkins works. The Neonatologist...